4//SEC Filing
Nielsen Ulrik B. 4
Accession 0001209191-17-052684
CIK 0001274792other
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 5:38 PM ET
Size
15.4 KB
Accession
0001209191-17-052684
Insider Transaction Report
Form 4
Nielsen Ulrik B.
SVP and CSO
Transactions
- Exercise/Conversion
Common Stock
2017-09-11$13.20/sh+14,756$194,779→ 37,437 total - Sale
Common Stock
2017-09-11$14.46/sh−14,756$213,372→ 22,681 total - Exercise/Conversion
Common Stock
2017-09-13$13.20/sh+6,800$89,760→ 29,481 total - Sale
Common Stock
2017-09-13$14.27/sh−6,800$97,036→ 22,681 total - Exercise/Conversion
Stock Option (right to buy)
2017-09-11−14,756→ 14,033 totalExercise: $13.20Exp: 2017-10-04→ Common Stock (14,756 underlying) - Exercise/Conversion
Stock Option (right to buy)
2017-09-13−6,800→ 7,233 totalExercise: $13.20Exp: 2017-10-04→ Common Stock (6,800 underlying)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $14.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F3]The one-for-ten reverse stock split of the Issuer's common stock that became effective for trading purposes on September 6, 2017 resulted in the reporting person's ownership of 204,130 fewer shares of common stock.
- [F4]This option was previously reported as covering 146,622 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.
- [F5]This option is fully vested.
Documents
Issuer
MERRIMACK PHARMACEUTICALS INC
CIK 0001274792
Entity typeother
Related Parties
1- filerCIK 0001531962
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 5:38 PM ET
- Size
- 15.4 KB